0HCK.LSE Align Technology, Inc.
- Market cap
- -
- P/E
- 17.1x
- P/B
- -
- ROE
- 11.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0HCK.LSE undervalued?
Graham numberThe Graham number of Align Technology, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Align Technology, Inc. fundamental analysis
No fundamental analysis for Align Technology, Inc. yet.
Align Technology, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Align Technology, Inc.
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of …
Full company profileAlign Technology, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Align Technology, Inc. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.08B | 1.47B | 1.97B | 2.41B | 2.47B | 3.95B | 3.73B | 3.86B | 4.00B | 4.03B | 4.15B |
| Gross Profit | 820M | 1.12B | 1.46B | 1.76B | 1.78B | 2.95B | 2.65B | 2.72B | 2.82B | 2.82B | 2.96B |
| Operating Income | 249M | 354M | 467M | 514M | 387M | 976M | 654M | 643M | 672M | 691M | 776M |
| EBITDA | 273M | 391M | 521M | 666M | 503M | 1.11B | 755M | 799M | 754M | 851M | 905M |
| Net Income | 190M | 231M | 400M | 443M | 1.78B | 772M | 362M | 445M | 421M | 410M | 475M |
| EPS | 2.33 | 2.83 | 4.92 | 5.53 | 22 | 9.69 | 4.61 | 5.81 | 5.62 | 5.65 | 6.69 |
| Balance Sheet | |||||||||||
| Total Assets | 1.40B | 1.78B | 2.05B | 2.50B | 4.83B | 5.94B | 5.95B | 6.08B | 6.21B | 6.23B | 6.52B |
| Total Liabilities | 401M | 630M | 800M | 1.15B | 1.60B | 2.32B | 2.35B | 2.45B | 2.36B | 2.18B | 2.22B |
| Shareholders' Equity | 995M | 1.15B | 1.25B | 1.35B | 3.23B | 3.62B | 3.60B | 3.63B | 3.85B | 4.05B | 4.31B |
| Cash & Short-term Investments | 641M | 722M | 735M | 869M | 961M | 1.17B | 1,000M | 973M | 1.04B | 1.09B | 1.14B |
| Total Debt | - | - | - | 59.2M | 86.2M | 125M | 127M | 127M | 119M | 114M | 112M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 248M | 439M | 555M | 747M | 662M | 1.17B | 569M | 786M | 738M | 593M | 688M |
| Capital Expenditure | 70.6M | 196M | 223M | 150M | 155M | 401M | 292M | 178M | 116M | 102M | 133M |
| Free Cash Flow | 177M | 243M | 331M | 598M | 507M | 771M | 277M | 608M | 623M | 491M | 555M |
| Ratios | |||||||||||
| ROE | 19.1% | 20.0% | 31.9% | 32.9% | 54.9% | 21.3% | 10.0% | 12.3% | 10.9% | 10.1% | 11.0% |
| ROA | 13.6% | 13.0% | 19.5% | 17.7% | 36.8% | 13.0% | 6.1% | 7.3% | 6.8% | 6.6% | 7.3% |
| Net Profit Margin | 17.6% | 15.7% | 20.4% | 18.4% | 71.8% | 19.5% | 9.7% | 11.5% | 10.5% | 10.2% | 11.4% |
| Debt to Equity | - | - | - | 0.04x | 0.03x | 0.03x | 0.04x | 0.03x | 0.03x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Align Technology, Inc. dividends
Align Technology, Inc. has not paid dividends in the last 9 fiscal years.
Who owns Align Technology, Inc.
- Insiders 6.13%
- Institutions 93.87%
- Public & others 0.00%
- Free float 66.8M
Align Technology, Inc. company profile
- Company name
- Align Technology, Inc.
- Ticker
- 0HCK.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 20,290
- Fiscal year end
- December
- Address
- 410 North Scottsdale Road, Tempe, AZ, United States, 85288
- Phone
- 602 742 2000
- Website
- aligntech.com
About Align Technology, Inc.
Align Technology, Inc. provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers Invisalign comprehensive package to treat adults and teens malocclusion and features, and orthodontic needs of teenage or younger patients; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients between the ages of six and ten years with a mixture of primary/baby and permanent teeth. This segment also provides Invisalign express, Invisalign lite, and Invisalign moderate; Invisalign Go, Invisalign Go express, and Invisalign Go Plus; retention products, Invisalign training, adjusting tools used by dental professionals during treatment, ancillary Invisalign accessory products, and other oral health products; Invisalign Professional Whitening system; Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; exocad, a computer-aided design and computer-aided manufacturing software; orthodontist software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers; and restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons. This segment also offers Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface for dental consultations; iTero TimeLapse technology for doctors or practitioners to compare a patient's historic 3D scans to the present-day scan; and subscription software, disposables, rents scanners, and pay per scan services. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
Align Technology, Inc. management
10- Mr. Joseph M. HoganPresident, CEO & Director · born 1957
- Mr. John F. MoriciCFO & Executive VP of Global Finance · born 1967
- Mr. Zelko RelicExecutive VP & CTO · born 1965
- Ms. Shirley StacyVice President of Corporate Communications & Investor Relations
- Richardson Jaime HolteExecutive Vice President of Global Human Resources
- Ms. Sreelakshmi KolliExecutive VP and Chief Product & Digital Officer · born 1975
- Mr. Srini KazaExecutive Vice President of Research & Development
- Dr. Mitra DerakhshanExecutive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services
- Mr. David CarrExecutive VP and MD of EMEA
- Mr. Frank QuinnExecutive VP & MD of Americas Region